What it's for (Indications)
- Fluorouracil, a pyrimidine analog antimetabolite, is a widely utilized antineoplastic agent in the treatment of various solid tumors.
- Its intravenous formulation is indicated for the palliative management of specific carcinomas, including but not limited to, metastatic colorectal cancer, breast cancer, gastric cancer, pancreatic cancer, and head and neck cancer.
- When administered intravenously, it is often used as a component of multi-drug chemotherapy regimens.
- The topical formulations of fluorouracil (cream and solution) are specifically indicated for the treatment of actinic keratoses and for the superficial basal cell carcinoma.
- The precise indication and regimen depend on the specific cancer type, stage, patient's overall health, and prior treatment history, requiring careful clinical assessment and selection by a qualified oncology professional.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage and administration of fluorouracil are highly individualized and depend significantly on the specific indication, route of administration (intravenous or topical), patient's body surface area (BSA), renal and hepatic function, hematologic status, and the chosen chemotherapy regimen. For intravenous administration, fluorouracil can be given as a rapid intravenous bolus, a continuous intravenous infusion over several hours or days, or as part of a more complex infusion schedule. Typical intravenous doses range from 200 mg/m² to 1000 mg/m², administered daily for several days or weekly, or as part of a 21- or 28-day cycle. Dose adjustments are frequently necessary based on observed toxicities, particularly myelosuppression and gastrointestinal side effects. For topical use, the cream or solution is applied to the affected skin areas once or twice daily for several weeks, with the duration of treatment dependent on the specific condition being treated and the patient's response and tolerance to therapy. Careful adherence to prescribed dosing and monitoring for adverse effects are paramount for safe and effective treatment outcomes. |
Safety & Warnings
Common Side Effects
- Fluorouracil treatment, particularly via intravenous administration, is associated with a wide spectrum of potential adverse effects, reflecting its systemic cytotoxic activity.
- Common and serious side effects include significant myelosuppression, manifesting as neutropenia, leukopenia, thrombocytopenia, and anemia, which can increase the risk of infection, bleeding, and fatigue.
- Gastrointestinal toxicities are prevalent, encompassing severe diarrhea, mucositis (stomatitis, esophagitis, pharyngitis), nausea, vomiting, and abdominal pain.
- Dermatological reactions such as hand-foot syndrome (palmar-plantar erythrodysesthesia), alopecia, skin rash, and photosensitivity are also frequently observed.
- Less common but serious systemic toxicities include cardiotoxicity (e.
- g.
- , angina, myocardial ischemia, arrhythmias, cardiomyopathy), neurotoxicity (e.
- g.
- , cerebellar ataxia, acute cerebral syndrome), ocular toxicity, and hepatotoxicity.
- Topical fluorouracil formulations cause localized skin reactions, including erythema, scaling, crusting, erosion, ulceration, pain, burning, and pruritus at the application site, which are generally expected and indicate treatment efficacy.
- Close monitoring and proactive management of these side effects are crucial for patient safety and treatment adherence.
Serious Warnings
- Black Box Warning: **WARNING: INCREASED TOXICITY WITH DIHYDROPYRIMIDINE DEHYDROGENASE (DPD) DEFICIENCY AND OTHER RISK FACTORS** Patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk for severe, life-threatening, or fatal toxicity when treated with fluorouracil due to the inability to metabolize the drug. Although the incidence is unknown, it is estimated that 3-5% of the population has partial DPD deficiency, and 0.2% may have complete DPD deficiency. Symptoms of severe fluorouracil toxicity include, but are not limited to, stomatitis, diarrhea, neutropenia, and neurotoxicity. Consider testing for DPD deficiency in patients with severe early-onset or unexpected toxicity. Discontinue fluorouracil therapy immediately if severe toxicity occurs. In addition, serious or fatal outcomes have been reported in patients with inadequate nutritional status, severe infection, or severe bone marrow depression. Fluorouracil should be used with extreme caution in patients with these risk factors. Closely monitor patients for signs of toxicity and manage appropriately, which may include dose reduction, treatment interruption, or discontinuation.
- Fluorouracil carries significant warnings due to its potent cytotoxic nature.
- Severe myelosuppression, including life-threatening neutropenia and thrombocytopenia, is a major dose-limiting toxicity and necessitates frequent monitoring of complete blood counts.
- Patients with known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency are at significantly increased risk for severe, life-threatening, or fatal toxicity due to impaired metabolism of fluorouracil, and screening for DPD deficiency should be considered prior to initiation of therapy.
- Severe gastrointestinal toxicity, including mucositis and diarrhea, can lead to dehydration, electrolyte imbalances, and systemic infection if not promptly managed.
- Cardiotoxicity, including angina, myocardial infarction, and arrhythmias, can occur, particularly in patients with pre-existing coronary artery disease.
- Neurotoxicity, although less common, can manifest as cerebellar ataxia or acute cerebral syndrome.
- Fluorouracil is teratogenic and genotoxic, posing a significant risk to fetal development, and should not be used during pregnancy.
- Effective contraception must be used by both male and female patients during and for a specified period after treatment.
- Patients should be warned about photosensitivity and advised to use sun protection.
How it Works (Mechanism of Action)
Fluorouracil (5-FU) is a fluorinated pyrimidine antimetabolite that exerts its cytotoxic effects by interfering with nucleic acid synthesis, specifically DNA and RNA. As a pro-drug, 5-FU undergoes intracellular enzymatic conversion to several active metabolites, primarily 5-fluorodeoxyuridine monophosphate (FdUMP), 5-fluorouridine triphosphate (FUTP), and 5-fluorodeoxyuridine triphosphate (FdUTP). FdUMP is a potent inhibitor of thymidylate synthase (TS), an enzyme critical for the de novo synthesis of thymidylate, which is an essential precursor for DNA synthesis. By inhibiting TS, FdUMP depletes intracellular thymidylate pools, thereby disrupting DNA replication and repair. Furthermore, FUTP can be aberrantly incorporated into RNA, leading to interference with RNA processing, ribosomal assembly, and protein synthesis. FdUTP can be incorporated into DNA, resulting in DNA strand breaks and functional impairment. These combined mechanisms ultimately lead to cell cycle arrest, inhibition of cell proliferation, and induction of apoptosis in rapidly dividing cancer cells, showcasing its effectiveness as an antineoplastic agent.
Commercial Brands (Alternatives)
No other brands found for this formula.